Characteristic	Imipenem	Meropenem	Aztreonam
Combination	Marketed with cilastatin	Does not require cilastatin	
Renal Dehydropeptidase Inhibition	Inhibited by cilastatin	Not sensitive to renal dehydropeptidase	
Resistance to B-lactamases	Resistant to hydrolysis by most ß-lactamases	Similar antimicrobial activity as Imipenem, with activity against some imipenem-resistant P. aeruginosa	Resistant to many ß-lactamases except those of Enterobacteriaceae
Anti-microbial Activity	- Active against penicillinase-producing strains of Staph. aureus - Inhibits most strains of Pseudomonas - Effective against Enterobacteriaceae but not carbapenemase-producing strains	Similar antimicrobial activity as Imipenem	Antimicrobial activity against gram-negative organisms like Pseudomonas aeruginosa, H. influenza, and Enterobacteriaceae. No activity against gram-positive organisms or anaerobes.
Pharmacokinetics	Given i.v. and hydrolyzed by renal dehydropeptidase. Cilastatin is added.	Does not require cilastatin, not sensitive to renal dehydropeptidase	-
Side Effects	Nausea, vomiting, and possibly seizures. Allergy risk in penicillin-allergic patients	Less likely to cause seizures	Patients sensitive to penicillins or cephalosporins do not react to Aztreonam
Therapeutic Uses	- Urinary tract infection - Lower respiratory tract infection - Intra-abdominal and gynecological infection - Soft tissue, bone, and joint infection - Treatment of Cephalosporin-resistant nosocomial infection	Similar therapeutic uses as Imipenem	Used in severe infections caused by gram-negative bacteria

Characteristic	Imipenem	Meropenem	Aztreonam
Combination	Marketed with cilastatin	Does not require cilastatin	
Renal Dehydropeptidase Inhibition	Inhibited by cilastatin	Not sensitive to renal dehydropeptidase	
Resistance to B-lactamases	Resistant to hydrolysis by most ß-lactamases	Similar antimicrobial activity as Imipenem, with activity against some imipenem-resistant P. aeruginosa	Resistant to many ß-lactamases except those of Enterobacteriaceae
Anti-microbial Activity	- Active against penicillinase-producing strains of Staph. aureus - Inhibits most strains of Pseudomonas - Effective against Enterobacteriaceae but not carbapenemase-producing strains	Similar antimicrobial activity as Imipenem	Antimicrobial activity against gram-negative organisms like Pseudomonas aeruginosa, H. influenza, and Enterobacteriaceae. No activity against gram-positive organisms or anaerobes.
Pharmacokinetics	Given i.v. and hydrolyzed by renal dehydropeptidase. Cilastatin is added.	Does not require cilastatin, not sensitive to renal dehydropeptidase	-
Side Effects	Nausea, vomiting, and possibly seizures. Allergy risk in penicillin-allergic patients	Less likely to cause seizures	Patients sensitive to penicillins or cephalosporins do not react to Aztreonam
Therapeutic Uses	- Urinary tract infection - Lower respiratory tract infection - Intra-abdominal and gynecological infection - Soft tissue, bone, and joint infection - Treatment of Cephalosporin-resistant nosocomial infection	Similar therapeutic uses as Imipenem	Used in severe infections caused by gram-negative bacteria